Publication Date
7-1-2022
Journal
Journal of Investigative Dermatology
DOI
10.1016/j.jid.2021.09.040
PMID
34890627
PMCID
PMC9174350
PubMedCentral® Posted Date
7-1-2023
PubMedCentral® Full Text Version
Author MSS
Published Open-Access
yes
Keywords
3' Untranslated Regions, Carcinoma, Squamous Cell, Cell Line, Tumor, Cell Proliferation, Gene Expression Regulation, Neoplastic, Humans, MicroRNAs, Proteoglycans, Receptors, Transforming Growth Factor beta, Skin Neoplasms, TGFβR3, miR-181a, epithelial-mesenchymal transition, cutaneous squamous cell carcinoma
Abstract
Cutaneous squamous cell carcinoma (cSCC) comprises 15‒20% of all skin cancers and has a well-defined progression sequence from precancerous actinic keratosis to invasive cSCC. To identify targets for chemoprevention, we previously reported a cross-species analysis to identify the transcriptional drivers of cSCC development and identified miR-181a as a potential oncomiR. We show that the upregulation of miR-181a promotes multiple protumorigenic properties by targeting an understudied component of TGFβ signaling, TGFβR3. miR-181a and TGFβR3 are upregulated and downregulated, respectively, in cSCC. miR-181a overexpression (OE) and TGFβR3 knockdown (KD) significantly suppresses UV-induced apoptosis in HaCaT cells and in primary normal human epidermal keratinocytes. In addition, OE of miR-181a or KD of TGFβR3 by short hairpin RNA enhances anchorage-independent survival. miR-181a OE or TGFβR3 KD enhances cellular migration and invasion and upregulation of epithelial‒mesenchymal transition markers. Luciferase reporter assays demonstrate that miR-181a directly targets the 3'-untranslated region of TGFβR3. miR-181a upregulates phosphorylated SMAD3 levels after TGFβ2 administration and results in elevated SNAIL and SLUG expression. Finally, we confirm in vivo that miR-181a inhibition compromises tumor growth. Importantly, these phenotypes can be reversed with TGFβR3 OE or KD in the context of miR-181a OE or KD, respectively, further highlighting the physiologic relevance of this regulation in cSCC.
Included in
Biological Phenomena, Cell Phenomena, and Immunity Commons, Life Sciences Commons, Medical Cell Biology Commons, Medical Microbiology Commons, Medical Molecular Biology Commons, Oncology Commons
Comments
Associated Data